Evidence map›Paper›PMID 39242838›Full record

ArticleNature immunology2024

The promise and reality of new immune profiling technologies.

Sara Suliman, David P Maison, Timothy J Henrich

Abstract read
PubMed Publisher
In one paragraph

Article in Nature immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Towards evidence-based immunology.Nature immunology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sara SulimanDivision of Experimental Medicine, University of California San Francisco, San Francisco, CA, USA. sara.suliman@ucsf.edu.ORCID http://orcid.org/0000-0002-5154-576X
David P MaisonDivision of Experimental Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-3428-1931
Timothy J HenrichDivision of Experimental Medicine, University of California San Francisco, San Francisco, CA, USA. timothy.henrich@ucsf.edu.ORCID http://orcid.org/0000-0002-6684-0622

Funding

The role of tyrosine metabolism in tuberculosis pathogenesisR01AI175614 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Sara Suliman · 2023 to 2026
$3.3M
Persistent Functional Immune Defects in Treated HIV InfectionK24AI145806 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HUNT, PETER W · 2020 to 2024
$921k
Mentoring Scientists for Careers in HIV Translational Clinical ResearchK24AI174971 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Timothy Jensen Henrich · 2023 to 2026
$766k
NIAID NIH HHS K24 AI174971U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) K24AI145806U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI175614
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Gene Expression ProfilingAllergy and Immunology

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.